(Q73327099)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

meta-analysis

0 references

title

Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

M Levi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M E Cromheecke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

E de Jonge

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M H Prins

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

B J de Mol

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

E Briët

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

H R Büller

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

English

0 references

publication date

1 December 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

354

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

9194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1940-1947

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group.

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Bleeding after cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

1 reference

7 January 2021

Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Desmopressin acetate following cardiopulmonary bypass: evaluation of coagulation parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

High-dose epsilon-aminocaproic acid versus aprotinin: antifibrinolytic efficacy in first-time coronary operations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application--clinical experience in 152 cardiac surgical patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

The effectiveness of low dose tranexamic acid in primary cardiac surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

The effect of preoperative tranexamic acid on blood loss after cardiac operations in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Effect of aprotinin on need for blood transfusion after repeat open-heart surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

High-dose aprotinin in cardiac surgery--a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Influence of High-dose Aprotinin Treatment on Blood Loss and Coagulation Patterns in Patients Undergoing Myocardial Revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Low-dose and high-dose aprotinin improve hemostasis in coronary operations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Recombinant aprotinin in coronary artery bypass graft operations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Randomised placebo controlled double blind study of two low dose aprotinin regimens in cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

The Impact of Aprotinin on Coronary Artery Bypass Graft Patency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Randomized, placebo-controlled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Postoperative aprotinin: effect on blood loss and transfusion requirements in cardiac operations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Re-graft patency and clinical efficacy of aprotinin in elective bypass surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Prophylactic treatment of postperfusion bleeding using EACA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Tranexamic acid reduces bleeding after cardiopulmonary bypass when compared to epsilon aminocaproic acid and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Desmopressin acetate is a mild vasodilator that does not reduce blood loss in uncomplicated cardiac surgical procedures.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Repeated dose administration of desmopressin acetate in uncomplicated cardiac surgery: a prospective, blinded, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

High-dose aprotinin therapy: a review of the first five years' experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2901264-7

7 January 2021

10.1016/S0140-6736(99)01264-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622296%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference